Chemotherapy-Induced Nausea and Vomiting Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Chemotherapy-Induced Nausea and Vomiting Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Chemotherapy-Induced Nausea and Vomiting Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Existing Drugs
Akynzeo (Netupitant-Palonosetron FDC)
Aloxi (Palonosetron)
Emend (Aprepitant)
Kytril Generic (Granisetron)
Zofran Generic (Ondansetron)
Pipeline Drugs
SUSTOL (Granisetron Injection extended release)
Rolapitant
Segment by Application
Serotonin Receptor Antagonists
NK1 Receptor Antagonists
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Merck & Co., Inc.
GlaxoSmithKline plc
Tesaro, Inc.
Helsinn Group
F. Hoffmann-La Roche Ltd.
Heron Therapeutics, Inc.
Dr. Reddy's Laboratories Ltd.
Acacia Pharma
Sun Pharmaceutical Industry Ltd.
Otsuka Holdings Co., Ltd.
